Lactobacillus plantarum lipoteichoic acid disrupts mature Enterococcus faecalis biofilm.


Journal

Journal of microbiology (Seoul, Korea)
ISSN: 1976-3794
Titre abrégé: J Microbiol
Pays: Korea (South)
ID NLM: 9703165

Informations de publication

Date de publication:
Apr 2020
Historique:
received: 01 11 2019
accepted: 23 12 2019
revised: 23 12 2019
pubmed: 29 1 2020
medline: 21 10 2020
entrez: 29 1 2020
Statut: ppublish

Résumé

Apical periodontitis is caused by biofilm-mediated root canal infection. Early phase oral bacterial biofilms are inhibited by Lactobacillus plantarum lipoteichoic acid (Lp.LTA). However, mature biofilms that develop over 3 weeks are more resistant to traditional endodontic medicaments. Therefore, this study examined the effectiveness of Lp.LTA on disrupting mature Enterococcus faecalis biofilms, and on enhancing the effects of endodontic medicaments. LTA was purified from L. plantarum through butanol extraction followed by hydrophobic and ion-exchange chromatography. E. faecalis biofilms were formed over 3 weeks on glass bottom dishes and in dentin blocks obtained from human single-rooted premolars. These mature biofilms were treated with or without Lp.LTA for 1 h, followed by additional treatment with either chlorhexidine digluconate (CHX), calcium hydroxide (CH), or triple antibiotics for 24 h. Biofilms on glass were live/dead stained and quantified by ZEN through confocal laser microscopy. Bio-films in dentin were fixed, sputter coated and analyzed by ImageJ with scanning electron microscopy. Preformed E. faecalis mature biofilms on the culture dishes were dose-dependently disrupted by Lp.LTA. Lp.LTA potentiated the effects of CHX or CH on the disruption of mature biofilm. Interestingly, CHX-induced disruption of preformed E. faecalis mature biofilms was synergistically enhanced only when pre-treated with Lp.LTA. Furthermore, in the dentin block model, Lp.LTA alone reduced E. faecalis mature biofilm and pre-treatment with Lp.LTA promoted the anti-biofilm activity of CHX. Lp.LTA could be an anti-biofilm or supplementary agent that can be effective for E. faecalis-biofilm-induced diseases.

Identifiants

pubmed: 31989544
doi: 10.1007/s12275-020-9518-4
pii: 10.1007/s12275-020-9518-4
doi:

Substances chimiques

Anti-Bacterial Agents 0
Lipopolysaccharides 0
Teichoic Acids 0
lipoteichoic acid 56411-57-5
chlorhexidine gluconate MOR84MUD8E
Calcium Hydroxide PF5DZW74VN
Chlorhexidine R4KO0DY52L

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

314-319

Références

Crit Rev Oral Biol Med. 2004 Nov 01;15(6):348-81
pubmed: 15574679
J Microbiol. 2019 Apr;57(4):310-315
pubmed: 30671742
Pediatr Infect Dis J. 2003 Aug;22(8):686-91
pubmed: 12913767
Toxicol Res. 2018 Jan;34(1):55-63
pubmed: 29372002
Ann Surg. 1990 Aug;212(2):155-9
pubmed: 2198000
J Endod. 2002 Apr;28(4):304-10
pubmed: 12043869
Int Immunopharmacol. 2009 Jan;9(1):127-33
pubmed: 19013542
J Endod. 2013 Apr;39(4):473-7
pubmed: 23522539
Pediatr Pulmonol. 2009 Jun;44(6):547-58
pubmed: 19418571
Appl Environ Microbiol. 2002 Sep;68(9):4194-200
pubmed: 12200265
Infect Immun. 2004 Jun;72(6):3658-63
pubmed: 15155680
J Antimicrob Chemother. 2008 Oct;62(4):730-7
pubmed: 18635521
Front Microbiol. 2018 Feb 27;9:327
pubmed: 29535693
J Endod. 2007 Aug;33(8):917-25
pubmed: 17878075
Infect Immun. 2013 Jul;81(7):2606-15
pubmed: 23649097
J Endod. 2017 Nov;43(11):1857-1861
pubmed: 28951032
J Endod. 2008 May;34(5):570-4
pubmed: 18436036
Australas J Dermatol. 2018 Feb;59(1):55-56
pubmed: 28589697
J Endod. 2019 Mar;45(3):310-315
pubmed: 30803538
J Endod. 2016 Feb;42(2):258-62
pubmed: 26577870
J Endod. 2011 Oct;37(10):1422-6
pubmed: 21924195
J Endod. 2011 May;37(5):657-61
pubmed: 21496666
Acta Odontol Scand. 2013 Sep;71(5):1255-60
pubmed: 23565703
J Endod. 2011 Feb;37(2):191-6
pubmed: 21238801
PLoS One. 2018 Feb 8;13(2):e0192694
pubmed: 29420616
World J Gastroenterol. 2007 Apr 7;13(13):1962-5
pubmed: 17461497
Int Endod J. 2002 Jan;35(1):13-21
pubmed: 11858203
Mol Immunol. 2015 Mar;64(1):183-9
pubmed: 25481370
J Endod. 2016 Oct;42(10):1503-8
pubmed: 27520407
Am J Public Health Nations Health. 1968 Sep;58(9):1713-22
pubmed: 5692059
J Endod. 2012 Oct;38(10):1376-9
pubmed: 22980181
Emerg Infect Dis. 1998 Apr-Jun;4(2):239-49
pubmed: 9621194
J Endod. 2009 Feb;35(2):212-5
pubmed: 19166775
Int Endod J. 2001 Jul;34(5):399-405
pubmed: 11482724
J Bacteriol. 2007 Nov;189(22):7945-7
pubmed: 17675377

Auteurs

A Reum Kim (AR)

Department of Oral Microbiology and Immunology, DRI, and BK21 Plus Program, School of Dentistry, Seoul National University, Seoul, 08826, Republic of Korea.

Minji Kang (M)

Department of Conservative Dentistry, School of Dentistry, Seoul National University, Seoul, 03080, Republic of Korea.

Yeon-Jee Yoo (YJ)

Department of Conservative Dentistry, School of Dentistry, Seoul National University, Seoul, 03080, Republic of Korea.

Cheol-Heui Yun (CH)

Department of Agricultural Biotechnology and Research Institute for Agriculture and Life Sciences, Seoul National University, Seoul, 08826, Republic of Korea.

Hiran Perinpanayagam (H)

Division of Restorative Dentistry, Schulich School of Medicine and Dentistry, University of Western Ontario, London, Canada.

Kee-Yeon Kum (KY)

Department of Conservative Dentistry, School of Dentistry, Seoul National University, Seoul, 03080, Republic of Korea. kum6139@snu.ac.kr.
National Dental Care Center for Persons with Special Needs, Seoul National University Dental Hospital for Persons with Special Needs, Seoul, 03080, Republic of Korea. kum6139@snu.ac.kr.

Seung Hyun Han (SH)

Department of Oral Microbiology and Immunology, DRI, and BK21 Plus Program, School of Dentistry, Seoul National University, Seoul, 08826, Republic of Korea. shhan-mi@snu.ac.kr.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH